Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
72 63 80 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
56 46 67 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 0 promises resolved, 5 needed for a score.
All types combined: 65 (likely 59 to 72, high confidence), from 73 claims: 42 factual claims, 31 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Jeremy Grantham's claims
“GMO has a strategy called Equity Dislocation, which goes long the very cheapest U.S. stocks and short an equal amount of the most overpriced, and which delivered a respectable double-digit positive return last year.”
Jeremy Grantham, GMO co-founder, writing in GMO viewpoint January 2023 After a Timeout, Back to the Meat Grinder! (GMO)
GMO's Equity Dislocation strategy, long the cheapest U.S. stocks and short an equal amount of the most overpriced, delivered a double-digit positive return in 2022.
Mostly true True in substance, wrong in a detail.
The evidence is the person's or their organisation's own records.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
The claim is about calendar year 2022 ('last year' as said in January 2023). TRUE: GMO's official performance records (fact sheet, quarterly letter or fund report for the Equity Dislocation strategy or fund) show a positive 2022 return of at least 10%, and the strategy is in substance long the cheapest U.S. stocks and short a roughly equal amount of the most expensive. MOSTLY TRUE: the 2022 return is at least 10%, but a minor detail of the description is off (for example the book is not exactly dollar-neutral, or it holds some non-U.S. names), or the figure reaches 10% gross but falls just short net of fees. MOSTLY FALSE: the 2022 return was positive but single-digit on every reported basis. FALSE: the 2022 return was zero or negative, or GMO had no such strategy running in 2022. A restated figure published by GMO governs.
Evidence
- [PDF] 2022: THE JOY OF MISSING OUT - GMO GMO Own record
“its double-digit returns last year.”
- [PDF] 2022: THE JOY OF MISSING OUT - GMO GMO Own record
“our Equity Dislocation Strategy – remains our favorite investment idea, despite”
- [PDF] 2022: THE JOY OF MISSING OUT - GMO GMO Own record
“But in 2022, deep value lost to shallow value by almost 5%, against an expected win of 10%.”
- GMO_TG_Spoilt for Choice_1-24 GMO LLC · 3 April 2025 Own record
“ANNUAL RETURNS Equity Dislocation Strategy Equity Dislocation Strategy Alternate Net FTSE 3-Mo. T-Bill Value Add vs. FTSE 3-Mo. T-Bill Alternate Net Value Add vs. FTSE 3-Mo. T-Bill MTD 3.78 3.67 0.45 +3.33 +3.22 2022 14.18 13.08 1.50 +12.68 +11.58”
- VALUE VS. GROWTH GMO Asset Allocation Insights · October 2022 Own record
“The Strategy is long the cheapest Value stocks and short the most expensive Growth stocks, and it is approximately beta neutral.”
- VALUE VS. GROWTH GMO Asset Allocation Insights · October 2022 Own record
“Preliminary performance for GMO’S Equity Dislocation Strategy was up 13.7% gross (11.9% net) over the same period.”
- GMO_TG_Spoilt for Choice_1-24 GMO LLC · 3 April 2025 Own record
“Portfolio includes U.S., EAFE, and EM names”
Reasoning
GMO's annual-returns table for the Equity Dislocation Strategy shows a 2022 return of 14.18%, or 13.08% on the alternate net series, both above 10% (E4). GMO's own quarterly letter also refers to the strategy's double-digit returns last year (E1, E2). The description is slightly off. GMO says the strategy is long the cheapest value stocks and short the most expensive growth stocks, and is approximately beta neutral (E5). A GMO slide also says the portfolio holds U.S., EAFE and emerging-market names, not only U.S. stocks (E7), which fits the 'mostly true' case in the criteria.
Cite this claim
Jeremy Grantham, “GMO's Equity Dislocation strategy, long the cheapest U.S. stocks and short an equal amount of the most overpriced, delivered a double-digit positive return in 2022.” (said January 2023). Verdict: mostly true. Reliability API, claim c_35eb5843be81, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_35eb5843be81
Claims without a verdict
- Unresolvable 148
- Not yet due 17
- Own records only 29
- Not researched 194
- Not checkable 543
Is a verdict here wrong, or do you speak for Jeremy Grantham? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.